Oral Drug Study In Women With Refractory Metastatic Breast Cancer After First-line or Second-line Herceptin.
Status:
Completed
Trial end date:
2005-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the efficacy of an oral investigational drug for
the treatment of metastatic breast cancer tumors that are known to overexpress HER2/neu.